THE LUGANO CLASSIFICATION
(DEAUVILLE CRITERIA) 1. i.e., maximum standardized uptake value (SUVmax) of the lesion >2x liver uptake Score 18-FDG uptake 1 No uptake 2 ≤ Mediastinal blood pool 3 > Mediastinum and ≤ liver 4 Moderately > liver at any site 5 Markedly1 > liver at any site and/or new sites of disease X New areas of uptake unlikely to be related to lymphoma
Download THE LUGANO CLASSIFICATION
Information
Domain:
Source:
Link to this page:
Documents from same domain
PRINCIPLES OF CHEMOTHERAPY IN CANCER
oncologypro.esmo.org1. NEOADJUVANT CHEMOTHERAPY [PREOPERATIVELY] Rationale •To make non-operable tumors operable •To achieve organ preservation •To select sensitivity for specific treatment (biomarkers) 2. ADJUVANT CHEMOTHERAPY [POSTOPERATIVELY] Rationale •To kill micrometastatic disease •To increase disease-free survival 3. PALLIATIVE CHEMOTHERAPY
EPIDEMIOLOGY OF BREAST CANCER IN AFRICA
oncologypro.esmo.orgEPIDEMIOLOGY OF BREAST CANCER IN AFRICA Joe-Nat Clegg-Lamptey School of Medicine and Dentistry, University of Ghana 1. I have no conflict of interest. Breast Cancer in Africa: Epidemiology •Incidence: Moderate but Increasing •Young age of patients •Advanced disease / Long duration of symptoms
CYP3A4 Inhibitor/Inducer Drug-drug Interactions for all ...
oncologypro.esmo.orgAfter discontinuation of a strong CYP3A4 inhibitor resume the dose that was taken prior to initiating the strong CYP3A4 inhibitor Avoid concurrent use of strong CYP3A inducers Crizotinib Ketoconazole Rifampicin Extreme caution should be taken if co-administration with a CYP3A4 inhibitor is unavoidable, the crizotinib dose should be
CLINICAL TRIAL ENDPOINTS - OncologyPRO
oncologypro.esmo.orgESMO Clinical Trials Tips and Tricks: Clinical Trial Endpoints Author: Ian Tannock, Steinar Aamdal, Dirk Arnold, Urania Dafni, Ulrich Keilholz, Morten Mau-Sørensen, Piotr Rutkowski, Stefan Sleijfer Subject: ESMO Clinical Trials Tips and Tricks: Clinical Trial Endpoints Created Date: 12/4/2015 12:53:31 PM
UNDERSTANDING CLINICAL TRIAL STATISTICS
oncologypro.esmo.orgUNDERSTANDING CLINICAL TRIAL STATISTICS. Prepared by Urania Dafni, Xanthi ... EaSt 6.3.1: a software package for the design and interim monitoring of group sequential clinical trials, Cytel Software Corporation, Cambridge, MA, ... Understanding Clinical Trials Statistics
Related documents
Deauville Criteria for end of therapy
www.lymphomapet.comDeauville Criteria for end of therapy Sally Barrington. 5 Point Scale /Deauville criteria 1. no uptake 2. uptake ≤mediastinum 3. uptake > mediastinum but ≤liver 4. moderately increased uptake compared to liver 5. markedly increased uptake compared to liver and/or new lesions.